跳至主要内容
临床试验/IRCT20200509047364N3
IRCT20200509047364N3尚未招募3 期

Evaluation of the efficacy of N-Acetylcysteine in severe COVID-19 patients: a randomized controlled phase III clinical trial

Bandare-abbas University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • All COVID-19 patients whose disease has been confirmed by the PCR test for SARS-Cov-2.
  • Having one of the criteria for severe COVID-19 disease includes tachypnea (respiration rate> 30 per minute), hypoxemia (O2 = saturation, arterial oxygen partial pressure ratio <300), pulmonary infiltration (> 50% of lung area during 24 48 h), LDH> 245 U / l, Progressive lymphopenia.
  • Hospitalized in the intensive care unit.
  • Signing the written consent of the study participant.

排除标准

  • Known allergy or hypersensitivity to N-Acetylcysteine.
  • The participant refused to participate in the continuation of the study.

研究者

发起方
Bandare-abbas University of Medical Sciences

相似试验

The effect of N-Acetylcysteine on COVID-19 | 临床试验